Pioneering health and security with frontier technologies.

For over two decades, we've partnered with bold founders at the earliest stages - those who embody the fundamental values of life and liberty by delivering frontier technologies to human health, security and intelligence.

Our Mission

PARTNER WITH US

Trailblazing founders need more than just surface-level support.

You deserve a partner who truly understands your vision and objectives.

Find out how ARTIS Ventures goes beyond to elevate our founders.

DISCOVER NEW DEPTHS

Founders who create new markets or redefine existing ones

Our Companies

Acquired

Scott Dylla & Brian Slingerland

Stemcentrx

Targeted therapies to eliminate cancer stem cells in solid tumors

Acquired

Steve Chen & Chad Hurley

YouTube

The leading global video-sharing platform

IPO

Alex Karp

Palantir

Connecting data, tech, humans and environments to change how groups analyze information

Dr. Jeff Chang & Doktor Gurson

Rad AI

Empowering radiologists with AI to save time, reduce burnout, and improve patient care

Ara Katz & Raja Dhir

Seed

Joshua Abram & Alan Murray

Conceivable

Max Hodak

Science

Kristin Muhlner

Affect Therapeutics

Marc Lajoie & Scott Boyken

Outpace Bio

Tyler Sweatt

Second Front Systems

Mohit Aron

Cohesity

Connor Landgraf

Eko

Global Resilience

We are funding a future where innovation is not only about breakthroughs and discovery—but about enabling global prosperity, health, and security. We believe innovation should deliver more than advancement; it should deliver impact.

We coined the term TechBio to capture the rise of innovation where technology meets biology. Today, Global Resilience is the next frontier, driven by founders leveraging tools like AI to create new markets or transform existing ones. It’s a bold vision—one that defines a generation of progress at the intersection of technological advancement, biology, and security. And while that mission is within reach, it demands we confront the structural bottlenecks and legacy systems that hinder acceleration.

Decades into our journey, our purpose is clear: to build global resilience by backing visionary founders shaping a safer, more prepared world. We partner with those transforming bold ideas into enduring solutions that protect and advance humanity.

discover GLOBAL RESILIENCE

Why Tech Bio+Health

Affecting everyday people

At ARTIS we invest in data-driven life sciences companies that solve problems affecting everyday people from across the globe. We care about scalable medical technologies backed by engineering, AI and strong datasets with broad indications for healthcare and life sciences.

Flexibility to pivot

Investing in companies with a Tech Bio+Health thesis ensures a plethora of indications from a singular biologically engineered approach, opening the door for increased revenue streams, optionality, intellectual property and flexibility to pivot in times of need.

Engineering-first approach

By combining the best of computer science and the powers of cellular biology, Tech Bio+Health is the engineering-first approach that enables cures instead of treatments, personalized therapeutics, more efficient drug discovery and powerful AI-machine led exploration of biological circuitry.